India's Drug Pricing Framework Termed 'Redundant' By GSK CEO
This article was originally published in PharmAsia News
Executive Summary
India should replace its drug pricing framework, U.K.-based GlaxoSmithKline CEO Andrew Witty said in an interview, calling the framework "redundant.